Results 51 to 60 of about 74,688 (254)

Mammalian target of rapamycin inhibition impacts energy homeostasis and induces sex‐specific body weight loss in humans

Journal of Cachexia, Sarcopenia and Muscle, 2023
Background Previous data from a 2‐year randomized controlled trial (CRAD001ADE12) indicated that mammalian target of rapamycin (mTOR) inhibition by everolimus slowed cyst growth in patients with autosomal‐dominant polycystic kidney disease (ADPKD ...
Marwan Mannaa, Pia Pfennigwerth, Jens Fielitz, Maik Gollasch, Michael Boschmann   +4 more
doaj   +1 more source

The Synergistic Effect of Tacrolimus (FK506) or Everolimus and Azoles Against Scedosporium and Lomentospora Species In Vivo and In Vitro

Frontiers in Cellular and Infection Microbiology, 2022
Scedosporium and Lomentospora infections in humans are generally chronic and stubborn. The use of azoles alone cannot usually inhibit the growth of these fungi.
Zikuo Wang, Mei Liu, Luyao Liu, Linyun Li, Lihua Tan, Yi Sun   +5 more
doaj   +1 more source

Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer [PDF]

, 2018
Background Endocrine therapies are the mainstay of treatment for oestrogen receptor (ER)-positive (ER+) breast cancer (BC). However, resistance remains problematic largely due to enhanced cross-talk between ER and growth factor pathways, circumventing ...
A Carracedo, A Subramanian, AH Evans, Allan Thornhill, Alshad S. Lalani, Aradhana Rani, C Trapnell, CK Osborne, CX Ma, Eugene Schuster, FL Chen, Francesca Avogadri-Connors, G Arpino, HJ Burstein, IE Smith, J Baselga, Joanna Nikitorowicz-Buniak, KE Bachman, KE O'Reilly, L Gandhi, LA Martin, LA Martin, Lesley-Ann Martin, LV Sequist, M Arnedos, M Dowsett, Mitch Dowsett, MT Weigel, N Patani, N Simigdala, NA O'Brien, Nikiana Simigdala, R Ribas, Ricardo Ribas, Richard E. Cutler, S Johnston, SC Drury, SN Mohd Nafi, SP Newman, Stephanie K. Guest, Stephen R. Johnston, Sunil Pancholi, T Nagashima, W Luo   +43 more
core   +6 more sources

MYCOPHENOLATE MOFETIL TREATMENT REDUCES THE RISK OF TREATMENT ESCALATION DUE TO VASCULAR COMPLICATIONS IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: EMULATION OF A TARGET TRIAL FROM ITALIAN RHEUMATOLOGY SOCIETY SPRING REGISTRY

Arthritis Care &Research, Accepted Article.
Objective Mycophenolate Mofetil (MMF) use in limited cutaneous systemic sclerosis (lcSSc) is relatively uncommon due to the lower fibrotic burden and the predominance of the vascular complications. In vitro observations and clinical data from transplanted patients suggest a protective effect of MMF on endothelial function.
Enrico De Lorenzis, Gerlando Natalello, Rossella De Angelis, Lucrezia Verardi, Dilia Giuggioli, Gianluigi Bajocchi, Lorenzo Dagna, Silvia Bellando‐Randone, Giovanni Zanframundo, Rosario Foti, Fabio Cacciapaglia, Giovanna Cuomo, Alarico Ariani, Edoardo Rosato, Gemma Lepri, Francesco Girelli, Valeria Riccieri, Elisabetta Zanatta, Ilaria Cavazzana, Francesca Ingegnoli, Maria De Santis, Giuseppe Murdaca, Giuseppina Abignano, Giorgio Pettiti, Alessandra Della Rossa, Maurizio Caminiti, Annamaria Iuliano, Giovanni Ciano, Lorenzo Beretta, Gianluca Bagnato, Ennio Lubrano, Maria Ilenia De Andres, Alessandro Giollo, Cosimo Bruni, Martina Orlandi, Marco Fornaro, Marta Saracco, Cecilia Agnes, Pier Giacomo Cerasuolo, Gabriella Alonzi, Edoardo Cipolletta, Federica Lumetti, Amelia Spinella, Luca Magnani, Corrado Campochiaro, Giacomo De Luca, Veronica Codullo, Elisa Visalli, Carlo Iandoli, Antonietta Gigante, Greta Pellegrino, Erika Pigatto, Maria‐Grazia Lazzaroni, Franco Franceschini, Elena Generali, Gianna Mennillo, Simone Barsotti, Giuseppa Pagano Mariano, Federica Furini, Licia Vultaggio, Simone Parisi, Clara Lisa Peroni, Gerolamo Bianchi, Enrico Fusaro, Gian Domenico Sebastiani, Marcello Govoni, Salvatore D'Angelo, Franco Cozzi, Fabrizio Conti, Serena Guiducci, Andrea Doria, Carlo Salvarani, Florenzo Iannone, Maria Antonietta D'Agostino, Clodoveo Ferri, Marco Matucci Cerinic, Silvia Laura Bosello, on behalf of SPRING collaborators   +77 more
wiley   +1 more source

K‐Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines

Molecular Oncology, 2017
Advanced biliary tract cancer (BTC) has a poor prognosis and limited treatment options. The PI3K/Akt/mTOR signalling pathway is hyperactivated in a subset of BTCs, and clinical activity of the mTOR inhibitor everolimus has been observed in some patients ...
Yvonne Yeung, David K. Lau, Fiona Chionh, Hoanh Tran, Janson W. T. Tse, Andrew J. Weickhardt, Mehrdad Nikfarjam, Andrew M. Scott, Niall C. Tebbutt, John M. Mariadason   +9 more
doaj   +1 more source

Telomerase Inhibition by Everolimus Suppresses Smooth Muscle Cell Proliferation and Neointima Formation Through Epigenetic Gene Silencing

JACC: Basic to Translational Science, 2016
Proliferation of smooth muscle cells (SMCs) during neointima formation is prevented by drug-eluting stents. The replicative capacity of mammalian cells is enhanced by telomerase expression; however, the contribution of telomerase to the proliferative ...
Jun Aono, MD, PhD, Ernesto Ruiz-Rodriguez, MD, Hua Qing, MD, Hannes M. Findeisen, MD, Karrie L. Jones, BS, Elizabeth B. Heywood, MS, Dennis Bruemmer, MD, PhD   +6 more
doaj   +1 more source

Optimal management of seizures associated with tuberous sclerosis complex: current and emerging options. [PDF]

, 2014
Seizures are clinically significant manifestations associated with 79%-90% of patients with tuberous sclerosis complex. Often occurring within the first year of life in the form of infantile spasms, seizures interfere with neuropsychiatric, social, and ...
Fallah, Aria, Wang, Shelly
core   +2 more sources

Combined Photothermal and mTOR‐Targeted Therapy Overcomes Immune Evasion and Enhances Checkpoint Blockade Efficacy in Metastatic Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
This study reveals that photothermal therapy, while inducing immunogenic cell death in triple‐negative breast cancer, paradoxically activates the oncogenic mTOR pathway to drive immune evasion. To counter this, a smart nanocomposite is engineered to co‐deliver localized hyperthermia and mTOR inhibition.
Yujie Zhao, Jing Yu, Xin Wang, Xu Liu, Fengli Zuo, Tianyue Xu, Leyi Tang, Ling Xiong, Li Li, Huifang Li, Xiaoting Chen, Guang Yang, Jing Jing, Xiaowei Liu   +13 more
wiley   +1 more source

Two cases of eczematous eruptions caused by everolimus

Journal of Cutaneous Immunology and Allergy, 2019
Objective Everolimus, an inhibitor of the mammalian target of rapamycin, has been used in the treatment of several types of tumor. Erythematous maculopapular and acneiform rashes are the major dermatological adverse events associated with everolimus ...
Minako Habu, Mikiko Tohyama, Koji Sayama
doaj   +1 more source

First-line therapy in HER2 positive metastatic breast cancer. Is the mosaic fully completed or are we missing additional pieces? [PDF]

, 2016
The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biology of breast cancer and the subsequent development of HER2-targeted therapies, have dramatically improved clinical outcomes for women with early-stage and advanced ...
Cognetti F., Fabi A., Malaguti P., Vari S.   +3 more
core   +2 more sources